We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Dowpharma Completes Technology Transfer to Cambrex

Dowpharma Completes Technology Transfer to Cambrex

Dowpharma Completes Technology Transfer to Cambrex

Dowpharma Completes Technology Transfer to Cambrex

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dowpharma Completes Technology Transfer to Cambrex"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cambrex Bio Science Baltimore, Inc., a subsidiary of Cambrex Corporation and DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company, has announced that they have entered into an agreement to utilize the Pfenex Expression Technology™, a Pseudomonas- based technology, from Dowpharma.

The relationship includes an initial technology transfer production run, the establishment of a standardized technology transfer package for customer projects, and the collaborative interactions between Cambrex, Dowpharma and third-party product companies to allow for Cambrex to manufacture biologic drug substances using the Pfenex Expression Technology.

"We expect Dowpharma's Pfenex Expression Technology to greatly increase protein expression levels in our customers' processes," said Frank Marchesani, Director of Sales and Business Development, Cambrex Biopharma business.

"The performance of the Pfenex Expression Technology in our initial production run confirmed the power of this exciting expression technology."

"Cambrex is impressed by the superior growth performance and expression characteristics of the Pfenex technology compared to conventional Escherichia coli based systems," added Christopher Dale, Ph.D., Vice President Technology, Cambrex Biopharma business.

"The complementary services offered by Dowpharma and Cambrex scientists, combined with standardized technology transfer protocols, will streamline the transition of customer projects from Dowpharma to Cambrex."

"We are pleased to work with Cambrex to help them leverage Pfenex Expression Technology to cost effectively deliver higher yields of their customers' therapeutic proteins," said Patrick Lucy, Business Leader, Microbial Biopharmaceuticals, Dowpharma.

"As a leading cGMP service provider, Cambrex will be an important part of the manufacturing network supporting the Pfenex Expression Technology."

Pfenex Expression Technology™ is built around modified strains of Pseudomonas fluorescens bacteria that increase cellular expression of recombinant proteins and peptides while maintaining critical solubility and activity characteristics.

Pfenex Expression Technology consistently outperforms other microbial systems, often with yields of five to ten times the next best expression alternative.